Although changes in SARAF transcripts or protein levels have been reported in a number of pathologies, including pancreatitis [113], cancer [111,114], and neurodegenerative [114,115,116] or cardiovascular [117,118,119,120,121] diseases, there is no direct indication that loss- or gain-of-function mutations in SARAF lead to any specific pathophysiology at this time. The gene discussed is SARAF; the disease is cancer.